Tambiciclib dimaleate

Overview

Tambiciclib (GFH009, JSH-009) dimaleate is an orally active, highly potent and selective CDK9 inhibitor ( IC 50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A / B , and excellent selectivity over 468 kinases/mutants. Tambiciclib dimaleate demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC , and inducing apoptosis . Tambiciclib dimaleate can be used for AML research.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > PARP | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > DYRK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcl-2 Family

Product Information

• Catalog No.: HY-X0009A
• CAS No.: 2559759-04-3
• Molecular Formula: C33H43ClN6O10S
• Molecular Weight: 751.25
• Purity: 99.53%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (3.33 mM); Clear solution
• Availability: In-stock

Source

Original product source